A PSEN1 genetic test rarely changes dementia care for someone whose symptoms begin after 65. PSEN1 (presenilin-1) is a gene linked to autosomal-dominant early-onset familial Alzheimer's disease, and its mutations cause a deterministic, highly penetrant disease pattern that almost always produces symptoms in a carrier's 40s or 50s, not after 65, according to slides from the University of Wisconsin Dementia Diagnostic Clinic Network.
For the much larger group of people diagnosed with dementia in their late 60s, 70s, or 80s, PSEN1 testing is not a useful screening tool at all. Pathology Tests Explained, an Australian clinical-pathology resource, states directly that PSEN1 testing has no value for the general population or for people with late-onset Alzheimer's disease. Care decisions for that group turn on a different gene entirely.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What PSEN1 Actually Tells You
- Why a Positive Result Rarely Applies After 65
- When PSEN1 Testing Does Matter, Regardless of Age
- Genetic Counseling Is Part of the Decision, Not an Afterthought
- PSEN1 Status Does Not Decide Eligibility for Newer Alzheimer's Drugs
- Frequently Asked Questions
What PSEN1 Actually Tells You
PSEN1 variants are the leading known cause of early-onset familial Alzheimer's disease (EOFAD), accounting for roughly 30% to 70% of EOFAD cases, with a sequence variant found in about 98% of tested EOFAD families, according to GeneReviews. That statistic describes families where multiple relatives developed dementia decades before typical retirement age, not sporadic cases that appear later in life. Carrying a disease-causing PSEN1 variant carries a lifetime disease risk cited as over 95%, and the gene behaves deterministically: if you inherit it, you are expected to develop symptoms, almost always before age 61, according to the University of Wisconsin Dementia Diagnostic Clinic Network.
This is different from PSEN2, where onset timing varies more and some carriers escape symptoms altogether. A 2025 study in Brain, drawing on the DIAN Observational Study and led by researchers including Niimi and McDade, modeled age-at-onset across 227 APP, PSEN1, and PSEN2 variants. It found that a variant's typical onset age combined with a parent's own onset age predicts when an individual carrier will likely become symptomatic — reinforcing that PSEN1-related planning is driven by a specific, often early, predicted age window rather than a flat cutoff at 65, per the DIAN/Brain 2025 summary.
Why a Positive Result Rarely Applies After 65
If a person has already reached 65 without symptoms and has no PSEN1-linked family history, a positive or negative PSEN1 result adds little to their care plan. The gene's near-total penetrance before 61 means an undiagnosed carrier reaching their mid-60s symptom-free is already an unusual outcome, and most dementia diagnosed at this age stems from other causes that PSEN1 does not explain. This is why insurers tie coverage so tightly to family history rather than age or symptoms alone.
Blue Shield of California's medical policy covers targeted PSEN1 testing for an asymptomatic person only when a first- or second-degree relative is a known carrier of a familial PSEN1 variant tied to early-onset disease; testing for general risk assessment outside that scenario is classified as investigational and not covered, according to Blue Shield of California's policy. Highmark's commercial policy draws a similar line from the diagnostic side: it covers PSEN1, PSEN2, and APP testing for people who are already symptomatic with dementia onset at or before age 65, and it requires genetic counseling before and after the test as a condition of coverage, according to Highmark's medical policy. Someone whose dementia symptoms began well past 65 typically falls outside this diagnostic pathway.
When PSEN1 Testing Does Matter, Regardless of Age
The scenario where a PSEN1 result changes care decisions is family-driven, not age-driven. If a parent or sibling carried a confirmed PSEN1 variant, a relative — even one who is over 65 and still symptom-free — may be offered testing to clarify their own risk and guide planning, consistent with Blue Shield's criteria above. A positive result in that setting supports concrete steps: A negative result in a family with a known PSEN1 variant is also decisive: it generally removes that specific inherited risk from the relative's own planning, though it does not rule out dementia from other causes.
- Scheduling earlier and more frequent cognitive monitoring, since onset timing can be estimated from the variant and family history, per the DIAN/Brain 2025 findings.
- Involving family in long-term care, legal, and financial planning before symptoms appear, since the mutation's high penetrance means planning has a clear trigger.
- Informing reproductive and family-planning decisions for younger relatives, since the condition is inherited in an autosomal-dominant pattern.
Genetic Counseling Is Part of the Decision, Not an Afterthought
Both the American College of Medical Genetics and the National Society of Genetic Counselors publish joint guidelines requiring structured counseling before and after Alzheimer's-related genetic testing, covering the psychosocial impact of a result, insurance discrimination risk, and implications for other family members, according to guidelines referenced in a University of Washington Memory and Brain Wellness Center presentation. This counseling step is why Highmark makes it a condition of coverage rather than an optional add-on.
The same presentation notes that growing use of direct-to-consumer genetic tests is bringing more people to their primary care doctors with PSEN1 and similar results to interpret, often with questions about whether the finding makes them eligible for newer dementia treatments. A result delivered without counseling can leave a person uncertain about what it actually means for their own care.
PSEN1 Status Does Not Decide Eligibility for Newer Alzheimer's Drugs
For people over 65 considering anti-amyloid drugs such as lecanemab or donanemab, the relevant genetic test is APOE, not PSEN1. U.S.
labeling allows treating APOE ε4 homozygotes with an added bleeding-risk warning, while European and UK guidance excludes APOE ε4 homozygotes from treatment altogether, according to commentary and a lab bulletin from Alberta Health Services. A person with a PSEN1 result but no APOE genotype on file does not have the information their care team needs to weigh these drugs. For most adults over 65 weighing dementia treatment options, asking about APOE genotyping — rather than PSEN1 — is the more directly useful question to raise with a physician.
Frequently Asked Questions
Should someone over 65 with no family history ask for PSEN1 testing?
Pathology Tests Explained states PSEN1 testing has no value as a screening test outside families with known early-onset familial Alzheimer's disease, so it adds nothing for someone without that family history.
Does a negative PSEN1 result mean a person won't develop dementia?
No. It generally rules out the specific inherited risk tied to a known familial PSEN1 variant but says nothing about other causes of dementia, including the sporadic late-onset forms most common after 65.
What genetic test matters for anti-amyloid drug eligibility?
APOE genotyping, not PSEN1, determines eligibility nuances for drugs like lecanemab and donanemab, according to Alberta Health Services' lab bulletin.
